XLVS:LSE:LSE-Invesco Health Care S&P US Select Sector UCITS ETF (USD)

ETF | Others |

Last Closing

USD 713.75

Change

-1.40 (-0.20)%

Market Cap

N/A

Volume

705.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-3.00 (-1.35%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+1.31 (+0.95%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.03 (-0.16%)

USD 588.35B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.14%)

USD 588.35B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+1.70 (+2.44%)

USD 266.08B
0QZO:LSE 0QZO

+1.30 (+1.18%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.03 (-0.10%)

USD 244.75B
0QZ3:LSE Qualcomm Inc.

-4.78 (-2.74%)

USD 202.26B
0R24:LSE Intel Corp.

+0.45 (+1.81%)

USD 196.14B

ETFs Containing XLVS:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.79% 76% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.79% 76% C+ 71% C-
Trailing 12 Months  
Capital Gain 0.70% 21% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.70% 17% F 33% F
Trailing 5 Years  
Capital Gain 52.08% 68% D+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.08% 66% D+ 74% C
Average Annual (5 Year Horizon)  
Capital Gain 10.77% 63% D 67% D+
Dividend Return 10.77% 62% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.67% 65% D 80% B-
Risk Adjusted Return 101.00% 88% B+ 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike